Method of Using MEK Inhibitor to Prevent Radiation Induced Fibrosis
AssigneeThomas Jefferson University
InventorsJoel Rosenbloom, Edward John Macarak
Life of this patent
Estimating the term…
Abstract
A method of reducing the severity of radiation induced fibrosis (RIF) by administering to a patient at least a first dose of an MeK inhibitor such as trametinib between 0.01 mg to 2.0 mg, and after said radiation procedure, administering to said patient a further dose of the MeK inhibitor between 0.01 mg and 2.0 mg after the radiation procedure.
Claims15
1-10. (canceled)
A method of reducing the severity of fibrosis formation due to radiation therapy comprising:
- administering to said patient at least a first dose of one or more MeK inhibitors between 0.01 mg to 2.0 mg prior to a first radiation therapy treatment, and after said radiation therapy treatment, administering to said patient a further dose of said one or more MeK inhibitors between 0.01 mg to 2.0 mg, daily, for at least seven days post radiation therapy treatment.
A method of treating a patient for development of excessive fibrin formation from radiation exposure comprising;
- administering to a patient an effective amount of one or more MeK inhibitors suitable to treat said fibrin formation;
- taking a sample from said patient in an area of possibly fibrin formation and detecting for the presence of alpha SMA and FNEDA;
- determining the levels of alpha SMA or FNEDA to confirm the presence or absence of the presence of myofibroblasts;
- administering at least an additional second dose of one or more MeK inhibitors when alpha SMA or FNEDA are detected in the sample.
A method of treating fibrosis due to radiation therapy comprising:
- taking a biopsy from a patient suspected to have fibrosis;
- determining the presence of Alpha SMA or FNEDA, administering to said patient an effective amount of one or more MeK inhibitors when the presence of Alpha SMA or FNEDA are confirmed in the biopsy sample.
Dependencies are inferred from the claim text.